Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV
Public ClinicalTrials.gov record NCT00001119. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Study of the Effects of Combination Antiretroviral Therapy in Acute HIV-1 Infection With an Emphasis on Immunological Responses
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to find out whether these powerful combinations of anti-HIV drugs are safe and effective for use in patients in the early stages of HIV infection and to find out how patients' immune systems react to HIV and anti-HIV drugs. Doctors generally treat patients in the early stages of HIV infection with the same anti-HIV drugs taken by patients who have had HIV for a long time. These drugs lower the level of HIV in the blood. However, doctors do not know whether patients who take anti-HIV drugs in the early stages of HIV infection actually live longer or have fewer AIDS-related diseases. This study will help doctors answer these questions. In the main study, doctors will look at how 2 different anti-HIV drug combinations affect the immune system. In the 2 substudies, doctors will look at how the body reacts to the hepatitis B vaccine and the tetanus vaccine. These substudies may help doctors learn how HIV-infected patients respond to new infections.
Study identification
- NCT ID
- NCT00001119
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Not applicable
- Enrollment
- 288 participants
Conditions and interventions
Conditions
Interventions
- Tetanus Toxoid Vaccine Biological
- Indinavir sulfate Drug
- Lamivudine/Zidovudine Drug
- Ritonavir Drug
- Abacavir sulfate Drug
- Amprenavir Drug
- Efavirenz Drug
- Hepatitis B Vaccine (Recombinant) Biological
- Lamivudine Drug
- Zidovudine Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 16 Years and older
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 30, 1999
- Primary completion
- May 31, 2004
- Completion
- Not listed
- Last update posted
- Mar 1, 2011
Started 1999
United States locations
- U.S. sites
- 11
- U.S. states
- 8
- U.S. cities
- 9
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| San Francisco Dept of Hlth / AIDS Office | San Francisco | California | 94102 | — |
| Univ of Illinois Chicago / Howard Brown Hlth Ctr | Chicago | Illinois | 60612 | — |
| Fenway Community Health Ctr / HIVNET | Boston | Massachusetts | 02115 | — |
| Univ of Minnesota | Minneapolis | Minnesota | 55455 | — |
| New York Univ Med Ctr | New York | New York | 10016 | — |
| Bronx-Lebanon Hosp Ctr | The Bronx | New York | 10453 | — |
| Univ of Cincinnati | Cincinnati | Ohio | 452670405 | — |
| Mem Hosp of Rhode Island | Pawtucket | Rhode Island | 02860 | — |
| Seattle HIVNET | Seattle | Washington | 98104 | — |
| Univ of Washington | Seattle | Washington | 98104 | — |
| Fred Hutchinson Cancer Research Ctr | Seattle | Washington | 98109 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00001119, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 1, 2011 · Synced Sep 10, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00001119 live on ClinicalTrials.gov.